Britain has asked its medicine regulator to assess Oxford University and AstraZeneca's COVID-19 vaccine candidate for temporary supply, a step towards beginning a roll-out before year's end.
Subscribe now for unlimited access.
$0/
(min cost $0)
or signup to continue reading
AstraZeneca expects 4 million doses to be available in Britain by the end of next month and Health Minister Matt Hancock is targeting the roll-out to begin before Christmas.
"We have formally asked the regulator to assess the Oxford/AstraZeneca vaccine, to understand the data and determine whether it meets rigorous safety standards," Hancock said in a statement on Thursday.
"This letter is an important step towards deploying a vaccine as quickly as safely possible."
Britain's Medicines and Healthcare products Regulatory Agency (MHRA) is already assessing the vaccine in a "rolling review" as data comes in on safety and efficacy.
Hancock has also asked the MHRA to approve the Pfizer/BioNTech candidate after it was shown to be 95 per cent effective.
Oxford and AstraZeneca published interim efficacy results on Monday, which showed the vaccine could be 90 per cent effective when given as a half dose followed by a full dose.
Questions have been raised about the Oxford/AstraZeneca data and robustness of that result, though the MHRA approved the use of the half-dose/full-dose regime a subgroup received in the trial.
Britain's top science adviser said on Thursday the interim results showed the Oxford/AstraZeneca vaccine worked.
"The headline result is the vaccine works and that's very exciting," Patrick Vallance said during a news conference with Prime Minister Boris Johnson.
Chief Medical Officer Chris Whitty said it was up to the regulator to make an assessment.
Australian Associated Press
